APPROVED OUTSIDE U.S. · NOT FDA-APPROVED

Cerebrolysin

A porcine brain-derived peptide complex used clinically in 50+ countries for stroke and dementia. Not FDA-approved. Western trials have produced mixed-to-positive signals; the picture isn't clear-cut.

Important: stroke and dementia are serious conditions that warrant proper neurology care

This page describes Cerebrolysin's international use in stroke recovery and dementia. People with active stroke, post-stroke disability, suspected dementia, or other neurological conditions should be working with neurology specialists. Cerebrolysin is not a substitute for evidence-based stroke care (acute treatment, rehabilitation, secondary prevention) or dementia care.

The 30-second read

Cerebrolysin is a peptide preparation made from purified pig brain tissue. It contains short peptides and amino acids designed to mimic the activity of natural neurotrophic factors. Manufactured by Ever Neuro Pharma (Austria) since the 1970s. Approved as a prescription drug in 50+ countries, including most of Europe, Russia, China, Mexico, and parts of Latin America, for stroke recovery, vascular dementia, Alzheimer's disease, and traumatic brain injury. The Western clinical-trial evidence has been mixed, with several Cochrane reviews concluding the data is inconclusive but suggestive of modest benefit in stroke recovery. Not FDA-approved. Used off-label in research-peptide circles for cognitive support and concussion recovery.

Why this peptide is on people's radar

Cerebrolysin sits in an unusual regulatory and evidence position. It's a real prescription drug with 50+ years of clinical use in much of the world, particularly post-Soviet, Asian, and Latin American medical systems. In those countries it's a routine part of post-stroke care and is also used for various forms of dementia and traumatic brain injury. Manufactured by Ever Neuro Pharma in Austria, it's standardized through a controlled enzymatic digestion of porcine brain tissue, producing a mixture of short peptides and amino acids that's intended to mimic the activity of brain-derived neurotrophic factors.

The Western evidence picture is genuinely mixed. Several Cochrane systematic reviews have examined Cerebrolysin trials in ischemic stroke and concluded that the available data is inconclusive but doesn't rule out modest benefit. Other reviews have been more skeptical, noting heterogeneity and methodological concerns. Large multinational trials including some Western centers (CERE-LYSE-1 in stroke) have produced positive trends without reaching the benchmarks needed for FDA approval. As a result, Cerebrolysin has continued international clinical use without crossing into U.S. or U.K. mainstream care.

In research-peptide and biohacker contexts, Cerebrolysin shows up off-label for concussion recovery, age-related cognitive decline, and ADHD-style attention concerns. The pharmaceutical-grade product is the same as the international clinical version; the use case is different from the FDA-style indication framework that the rest of the peptide world operates under.

What people are usually trying to do with it

Two distinct groups of users:

  • Internationally-approved clinical use: stroke recovery, vascular dementia, Alzheimer's disease, traumatic brain injury
  • Off-label use in research-peptide / biohacker contexts: concussion recovery, post-concussion syndrome, age-related cognitive decline, attention concerns
  • Adjunctive support after acute neurological events
  • Cognitive support in older adults outside the indications above

What the science actually shows

Plain-English summary:

Stroke recovery (international approval)

Multiple trials and pooled analyses have reported improvements in functional recovery scales when Cerebrolysin is given in the early post-stroke period. Cochrane reviews have judged the data inconclusive but suggestive.1

Alzheimer's and vascular dementia

International trials have reported cognitive benefits in dementia populations. Western methodological standards haven't been fully met for FDA approval.2

Traumatic brain injury

Smaller trials in TBI have reported benefits in functional recovery. Used in many international neurology practices for moderate-severe TBI.3

Mechanism (proposed)

The peptide complex is thought to mimic brain-derived neurotrophic factors (BDNF and similar), supporting neuronal survival and plasticity. Specific mechanism is less precisely characterized than for single-molecule peptides because Cerebrolysin is a complex.

What hasn't been demonstrated

FDA approval. Western trials at the methodological standard required for FDA review. Use case in healthy adults seeking general cognitive support. Long-term safety beyond the documented international clinical use experience.

The honest read

What's solid:

Cerebrolysin is a real prescription drug with 50+ years of international clinical use. The international evidence base is meaningful, and the stroke-recovery use case is supported by international Cochrane-reviewed evidence as suggestive of modest benefit.

What's still being worked out:

Whether the effect sizes seen in international trials would meet FDA approval standards. Methodological heterogeneity in the trial literature has been a real concern. Western mainstream neurology has not adopted Cerebrolysin into routine practice.

What's hyped beyond the evidence:

Cerebrolysin as a general "brain optimizer" for healthy adults. The clinical evidence is in defined patient populations with measurable neurological dysfunction. Healthy-adult cognitive enhancement use is far less established than the stroke or dementia use cases.

Things to know if you're looking into it

  • Stroke and dementia care matters: if you have an active stroke or are concerned about dementia in yourself or a family member, work with a neurology team using mainstream evidence-based care first.
  • How it's used clinically: intravenous or intramuscular injection in courses (typical international protocol: 10-30 mL daily for 10-20 days, repeated as cycles).
  • Regulatory status: approved in 50+ countries internationally. Not FDA-approved. Not on the FDA Category 2 list (compounded versions exist outside FDA drug-approval framework).
  • Reported tolerability: generally favorable across decades of international use. Mild and uncommon side effects.
  • Healthcare provider involvement: essential for any neurological condition. Cerebrolysin is a prescription drug in the countries where it's approved.
  • Specific dosing protocols, mechanism, and the full reference list: all in the "Want to go deeper?" section below.

What people often ask

Is Cerebrolysin FDA-approved?

No. Approved in 50+ countries internationally, including most of Europe, Russia, China, Mexico, and parts of Latin America, but not by the FDA in the United States.

Does it help stroke recovery?

International clinical use suggests yes; Cochrane reviews have called the evidence inconclusive but suggestive of modest benefit. Western trials haven't met the standard for FDA approval. Anyone with a stroke history should be working with neurology and rehabilitation specialists.

Can it treat or prevent dementia?

International trials have reported cognitive benefits in dementia populations. The data is suggestive but not at FDA-approval standards. Anyone concerned about dementia should be working with neurology specialists for proper diagnosis and treatment.

Is it safe?

50+ years of international clinical experience supports a generally favorable safety profile. Long-term safety in healthy adults using it for off-label cognitive enhancement is less well-characterized.

How is it different from Russian peptides like Semax or Pinealon?

Different category. Cerebrolysin is a porcine-brain-derived peptide-and-amino-acid complex used in mainstream international neurology. Semax and Pinealon are synthetic single peptides from a Russian research tradition. Different drug substances, different evidence bases, somewhat overlapping use cases.

Why isn't it FDA-approved?

The Western trial program hasn't met FDA standards for efficacy in any single indication. Methodological concerns about heterogeneity and trial design have been raised. The complex nature of the drug substance (vs a single defined molecule) also creates challenges for FDA-style approval.

FDA and regulatory status

Status as of May 5, 2026: Not FDA-approved. Approved as a prescription medication in 50+ countries internationally for indications including ischemic stroke, vascular dementia, Alzheimer's disease, and traumatic brain injury. Manufactured by Ever Neuro Pharma (Austria). Status updates land here when they happen.

Want to go deeper? Mechanism, dosing, the international clinical experience, and references.

Background

Cerebrolysin is a peptide preparation derived from purified porcine brain tissue through standardized enzymatic digestion. The product contains a mixture of short peptides (with molecular weights below 10 kDa) and free amino acids. Manufactured by Ever Neuro Pharma since the 1970s and used in clinical neurology in much of the world.

Mechanism of action

Proposed to mimic the activity of brain-derived neurotrophic factors. Animal and cell-culture studies report neuroprotective effects in models of ischemic injury, oxidative stress, and excitotoxicity. The mechanism is less precisely characterized than for single-molecule drugs because Cerebrolysin is a complex preparation.

International clinical dosing

IV or IM injection. Typical stroke protocol: 30 mL daily IV for 10-21 days starting in the early post-stroke period. Dementia protocols use 10-30 mL daily for 10-20 days, repeated as cycles 2-3 times per year.

References

  1. Heiss WD, Brainin M, Bornstein NM, et al. (2012). "Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial." Stroke, 43(3), 630–636. PubMed
  2. Alvarez XA, Cacabelos R, Sampedro C, et al. (2011). "Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin." Eur J Neurol, 18(1), 59–68. PubMed
  3. Muresanu DF, Ciurea AV, Gorgan RM, et al. (2020). "A retrospective, multi-center cohort study evaluating the severity- related effects of Cerebrolysin treatment on clinical outcomes in traumatic brain injury." CNS Neurol Disord Drug Targets, 19(3), 187–195. PubMed
  4. Ziganshina LE, Abakumova T, Hoyle CH. (2020). "Cerebrolysin for acute ischaemic stroke." Cochrane Database Syst Rev, 7(7), CD007026. PubMed
For educational and research purposes only. This is not medical advice. Cerebrolysin is approved internationally but not FDA-approved. Stroke, dementia, traumatic brain injury, and other serious neurological conditions should be evaluated and treated by qualified neurology specialists using evidence-based care. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does.